PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
- 13 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (22), 5843-5851
- https://doi.org/10.1158/1078-0432.ccr-20-1731
Abstract
Purpose: We explored the prognostic effect of PIK3CA mutation in HER2-positive patients enrolled in the ShortHER trial. Experimental Design: The ShortHER trial randomized 1253 patients with HER2-positive breast cancer to 9-weeks or 1-year of adjuvant trastuzumab combined with chemotherapy. PIK3CA hot-spot mutations in exon 9 and 20 were analysed by Pyrosequencing. Expression of 60 genes, including PAM50 genes was measured using the nCounter platform. Results: A mutation of the PIK3CA gene was detected in 21.7% of the 803 genotyped tumors. At a median follow up of 7.7 years, 5-yr disease-free survival (DFS) rates were 90.6% for PIK3CA mutated and 86.2% for PIK3CA wild-type tumors (HR 0.84, 95%CI 0.56-1.27, P=0.417). PIK3CA mutation showed a favorable prognostic impact in the PAM50 HER2-enriched subtype (n=232): 5-yr DFS 91.8% vs 76.1% (log-rank P=0.049; HR 0.46 95%CI 0.21-1.02). HER2-enriched/ PIK3CA mutated vs wild-type tumors showed numerically higher tumor infiltrating lymphocytes (TILs) and significant upregulation of immune-related genes (including CD8A, CD274, PDCD1 and MYBL2, a proliferation gene involved in immune processes). High TILs as well as the upregulation of PDCD1 and MYBL2 were associated with a significant DFS improvement within the HER2-enriched subtype (HR 0.82, 95%CI 0.68-0.99, P=0.039 for 10% TILs increment; HR 0.81, 95%CI 0.65-0.99, P=0.049 for PDCD1 expression; HR 0.72, 95%CI 0.53-0.99, P=0.042 for MYBL2 expression). Conclusions: PIK3CA mutation showed no prognostic impact in the ShortHER trial. Within the HER2-enriched molecular subtype, patients with PIK3CA mutated tumors showed better DFS vs PIK3CA wild-type that may be partly explained by upregulation of immune-related genes.Keywords
Other Versions
Funding Information
- Agenzia Italiana del Farmaco (FARM62MC97)
- Italian Association for Cancer Research (MFAG 2014 - 15938)
- Instituto de Salud Carlos III (P116/00904)
- Breast Cancer Now (2018NOVPCC1294)
This publication has 28 references indexed in Scilit:
- PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2015
- Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 TrialJournal of Clinical Oncology, 2015
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast CancerJournal of Clinical Oncology, 2014
- PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsBreast Cancer Research, 2014
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast CancerJNCI Journal of the National Cancer Institute, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- Direct multiplexed measurement of gene expression with color-coded probe pairsNature Biotechnology, 2008
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistanceMolecular Cancer Therapeutics, 2007